Phase 2 study of ATRA and arsenic trioxide for acute promyelocytic leukemia

Phase 2 study of ATRA and arsenic trioxide for acute promyelocytic leukemia - Phase 2 study of ATRA and arsenic trioxide for acute promyelocytic leukemia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012004

Enrollment

Registered

2013-10-09

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute promyelocytic leukemia

Interventions

all-trans retinoic acid idarubicin arsenic trioxide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed APL (FAB: M3 or M3v) 2. Performance status (ECOG): 0-2 3. Adequate cardiac, pulmonary, hepatic and renal function 4. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Severe co-morbidity 2. Pregnant and/or lactating woman 3. Patients who have a difficulty to enter the study.

Design outcomes

Primary

Measure	Time frame
Complete remission rate (CR)	—

Countries

Japan

Contacts

Public ContactJun Imagawa

Hiroshima University Hospital Department of Hematology

imagawa@hiroshima-u.ac.jp082-257-5861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026